Shares of Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) were up 6.3% on Monday. The stock traded as high as $12.40 and last traded at $12.40. 400 shares changed hands during trading, a decline of 90% from the average session volume of 4,129 shares. The stock had previously closed at $11.67.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $20.00.
Get Our Latest Research Report on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Performance
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for cancer imaging and treatment. Its platform combines radioactive isotopes with targeting molecules designed to identify or bind to specific biological markers associated with disease.
The company’s principal commercial product is Illuccix, a gallium-68 PSMA-PET imaging agent used to help detect and manage prostate cancer. Telix is also developing a pipeline of diagnostic and therapeutic radiopharmaceuticals targeting cancers including kidney, brain, and prostate tumors, as well as other medical conditions.
Founded in 2015 and headquartered in Melbourne, Australia, Telix serves healthcare markets across Australia, the United States, Europe, and other international regions through regulatory approvals, commercial partnerships, and distribution arrangements.
See Also
- Five stocks we like better than Telix Pharmaceuticals
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
